These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21170988)

  • 1. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
    Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
    Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
    Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
    Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
    PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
    Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
    Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
    Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
    Kawada J; Zou P; Mazitschek R; Bradner JE; Cohen JI
    J Biol Chem; 2009 Jun; 284(25):17102-17109. PubMed ID: 19386607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
    Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
    J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis.
    Mitarnun W; Suwiwat S; Pradutkanchana J; Saechan V; Ishida T; Takao S; Mori A
    Am J Hematol; 2002 May; 70(1):31-8. PubMed ID: 11994979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
    Shen L; Au WY; Guo T; Wong KY; Wong ML; Tsuchiyama J; Yuen PW; Kwong YL; Liang RH; Srivastava G
    Blood; 2007 Jul; 110(1):469-70. PubMed ID: 17579189
    [No Abstract]   [Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.